Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature - PubMed (original) (raw)
Review
. 2013 Oct;137(10):1326-36.
doi: 10.5858/arpa.2012-0525-OA.
Affiliations
- PMID: 24079759
- DOI: 10.5858/arpa.2012-0525-OA
Free article
Review
Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature
Bin Xu et al. Arch Pathol Lab Med. 2013 Oct.
Free article
Abstract
Context: Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase mediating chromatin condensation and epigenetic modulation, is overexpressed in various human carcinomas and is associated with adverse clinicopathologic characteristics and biologic behavior. The expression of EZH2 in renal cell carcinomas (RCCs) has not been fully characterized yet.
Objective: To evaluate the prognostic role of EZH2 in RCC by analyzing the immunohistochemical staining pattern of the marker in relation to pathologic features and clinical outcome.
Design: We correlated the immunolabeling of EZH2 with multiple clinicopathologic features, including Fuhrman nuclear grade, pathologic stage, metastatic status, and clinical outcome in 223 clear cell RCCs (CRCCs) and 21 papillary RCCs, by using tissue microarrays of primary and metastatic cases.
Results: Most CRCCs (75%) showed positive EZH2 staining, with most primary tumors showing focal staining in comparison to nonfocal staining in metastatic cases. In primary tumors, EZH2 expression was associated with higher nuclear grade and lower pathologic stage. Metastatic tumors showed a higher number of positive cases (81% versus 67%) and a more diffuse and more intense pattern of staining than primary CRCCs. For the 22 locally advanced primary tumors (T3/4) and 43 metastatic RCCs, patients who experienced RCC-related deaths significantly overexpressed the marker in comparison to patients who did not experience RCC-related mortality.
Conclusions: By showing that EZH2 expression is associated with increased metastatic potential and a worse clinical outcome, this study suggests that EZH2 can serve as a prognostic biomarker for RCC, thus confirming it as a key molecule driving oncogenesis and metastasis.
Similar articles
- Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y, Chen Y, Geng H, Qi C, Liu Y, Yue D. Wang Y, et al. Tumour Biol. 2015 Sep;36(9):7159-66. doi: 10.1007/s13277-015-3417-z. Epub 2015 Apr 17. Tumour Biol. 2015. PMID: 25877750 - Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J, Guo J. Liu L, et al. BJU Int. 2016 Feb;117(2):351-62. doi: 10.1111/bju.12702. Epub 2015 Apr 21. BJU Int. 2016. PMID: 24612432 - Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
Lee HW, Choe M. Lee HW, et al. Pathol Int. 2012 Nov;62(11):735-41. doi: 10.1111/pin.12001. Pathol Int. 2012. PMID: 23121604 - Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.
Bian EB, Li J, He XJ, Zong G, Jiang T, Li J, Zhao B. Bian EB, et al. Expert Opin Ther Targets. 2014 Oct;18(10):1197-206. doi: 10.1517/14728222.2014.941807. Epub 2014 Jul 21. Expert Opin Ther Targets. 2014. PMID: 25046371 Review. - Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
Semeniuk-Wojtaś A, Stec R, Szczylik C. Semeniuk-Wojtaś A, et al. Urol Oncol. 2016 May;34(5):215-20. doi: 10.1016/j.urolonc.2015.12.013. Epub 2016 Feb 2. Urol Oncol. 2016. PMID: 26850779 Review.
Cited by
- Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2.
Lachat C, Boyer-Guittaut M, Peixoto P, Hervouet E. Lachat C, et al. Epigenomes. 2018 Dec 20;3(1):1. doi: 10.3390/epigenomes3010001. Epigenomes. 2018. PMID: 34991274 Free PMC article. Review. - CURLY LEAF Regulates Gene Sets Coordinating Seed Size and Lipid Biosynthesis.
Liu J, Deng S, Wang H, Ye J, Wu HW, Sun HX, Chua NH. Liu J, et al. Plant Physiol. 2016 May;171(1):424-36. doi: 10.1104/pp.15.01335. Epub 2016 Mar 4. Plant Physiol. 2016. PMID: 26945048 Free PMC article. - H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
Day CA, Hinchcliffe EH, Robinson JP. Day CA, et al. Cells. 2022 Oct 26;11(21):3376. doi: 10.3390/cells11213376. Cells. 2022. PMID: 36359771 Free PMC article. Review. - The role of histone methylation in renal cell cancer: an update.
Hou Y, Yuan Y, Li Y, Wang L, Hu J, Liu X. Hou Y, et al. Mol Biol Rep. 2023 Mar;50(3):2735-2742. doi: 10.1007/s11033-022-08124-3. Epub 2022 Dec 28. Mol Biol Rep. 2023. PMID: 36575323 Review. - Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.
Chen K, Xiao H, Zeng J, Yu G, Zhou H, Huang C, Yao W, Xiao W, Hu J, Guan W, Wu L, Huang J, Huang Q, Xu H, Ye Z. Chen K, et al. Clin Cancer Res. 2017 Jul 1;23(13):3428-3441. doi: 10.1158/1078-0432.CCR-16-2020. Epub 2016 Nov 22. Clin Cancer Res. 2017. PMID: 27879367 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical